Zobrazeno 1 - 10
of 603
pro vyhledávání: '"Charles L Loprinzi"'
Autor:
Yuchiao Chang, Joshua R Lakin, James A Tulsky, Elise N Brannen, Michael K Paasche-Orlow, Charlotta Lindvall, Daniel A Gundersen, Areej El-Jawahri, Angelo Volandes, Julie Goldman, Brian Sipin, Michael J Barry, Kathryn I Pollak, Miji Sofela, Danielle Kennedy, S. Yousuf Zafar, Maria Torroella Carney, Diana Martins-Welch, Michael Qiu, Jody-Ann McLeggon, Craig E Devoe, Jon C. Tilburt, Charles L Loprinzi, Parvez A. Rahman, Jeremiah J. Stout, Aretha Delight Davis, Lisa M. Quintiliani
Publikováno v:
BMJ Open, Vol 10, Iss 7 (2020)
Introduction Advance care planning (ACP) is associated with improved health outcomes for patients with cancer, and its absence is associated with unfavourable outcomes for patients and their caregivers. However, older adults do not complete ACP at ex
Externí odkaz:
https://doaj.org/article/95fd03f0d5b44ae0a30af5e4db2619fb
Autor:
Ciara C. O’Sullivan, Nicole L. Larson, Robert A. Vierkant, Mary Lou Smith, Cynthia Chauhan, Fergus J. Couch, Janet E. Olson, Charles L. Loprinzi, Kathryn J. Ruddy
Publikováno v:
Archives of Public Health, Vol 82, Iss 1, Pp 1-16 (2024)
Abstract Purpose The aims of the Advocate-BREAST project are to study and improve the breast cancer (BC) patient experience through education and patient-centered research. Methods In December 2021, an electronic REDCap survey was circulated to 6,918
Externí odkaz:
https://doaj.org/article/35f0f2fb820841898dc9f3870f5db4f6
Publikováno v:
International Journal of Women's Health, Vol 2010, Iss default, Pp 123-135 (2010)
Deirdre R Pachman1, Jason M Jones1, Charles L Loprinzi21Internal Medicine, Mayo Clinic, Rochester, MN, USA; 2Medical Oncology, Mayo Clinic, Rochester, MN, USAAbstract: Hot flashes are one of the most common and distressing symptoms associated with me
Externí odkaz:
https://doaj.org/article/27b27b57cd764a0caa1630aab200cc94
Autor:
Samantha Mannion, Alexandra Higgins, Nicole Larson, Elizabeth A. Stewart, Zaraq Khan, Chandra Shenoy, Hazel B. Nichols, H. Irene Su, Ann H. Partridge, Charles L. Loprinzi, Fergus Couch, Janet E. Olson, Kathryn J. Ruddy
Publikováno v:
Scientific Reports, Vol 14, Iss 1, Pp 1-9 (2024)
Abstract Survey data from the Mayo Clinic Breast Disease Registry were used to assess fertility counseling and fertility preservation strategies in a modern cohort of young women with breast cancer. One hundred respondents were identified who were un
Externí odkaz:
https://doaj.org/article/86b7b4f987234257abdef6e562248c89
Autor:
Lauren E Ta, James D Schmelzer, Allan J Bieber, Charles L Loprinzi, Gary C Sieck, Jill D Brederson, Philip A Low, Anthony J Windebank
Publikováno v:
PLoS ONE, Vol 8, Iss 1, p e54161 (2013)
Chemotherapy-induced neuropathy is the principle dose limiting factor requiring discontinuation of many chemotherapeutic agents, including cisplatin and oxaliplatin. About 30 to 40% of patients receiving chemotherapy develop pain and sensory changes.
Externí odkaz:
https://doaj.org/article/256e9ff96f234fc4b238fc8489eb1e9f
Autor:
Elizabeth J. Cathcart‐Rake, David Zahrieh, Deanne Smith, Susan Young, Shaylene McCue, Amanda O'Connor, Stephan Thomé, Mario Lacouture, Terra Register, Jill Piens, Bret B. Friday, Charles L. Loprinzi
Publikováno v:
Cancer Medicine, Vol 12, Iss 8, Pp 9650-9654 (2023)
Abstract Introduction Nasal symptoms are frequently reported by patients undergoing chemotherapy. Methods Eligible patients planning to receive paclitaxel, docetaxel, nab‐paclitaxel, bevacizumab without a concomitant taxane, or “other” (non‐t
Externí odkaz:
https://doaj.org/article/eef6427d42514b0c9fd6e63b398eebf1
Autor:
David Zahrieh, Daniel Satele, Ellen M. Lavoie Smith, Charles L. Loprinzi, Jennifer Le-Rademacher
Publikováno v:
Cancers, Vol 14, Iss 5, p 1212 (2022)
While oxaliplatin-induced peripheral neuropathy (OIPN) is more common and severe in patients who receive the previous standard, 6-month oxaliplatin-based treatment, we hypothesized that OIPN was still pervasive in patients who received shorter, 3-mon
Externí odkaz:
https://doaj.org/article/85d1f83fdd3b48838f54ecd9a82571fa
Autor:
Allison M. Quick, Andrew Hundley, Cynthia Evans, Julie A. Stephens, Bhuvaneswari Ramaswamy, Raquel E. Reinbolt, Anne M. Noonan, Jeffrey Bryan Van Deusen, Robert Wesolowski, Daniel G. Stover, Nicole Olivia Williams, Sagar D. Sardesai, Stephanie S. Faubion, Charles L. Loprinzi, Maryam B. Lustberg
Publikováno v:
Journal of Clinical Medicine, Vol 11, Iss 3, p 774 (2022)
(1) Background: The objective of this study was to determine the long-term efficacy of fractional CO2 laser therapy in breast cancer survivors. (2) Methods: This was a single-arm study of breast cancer survivors. Participants received three treatment
Externí odkaz:
https://doaj.org/article/6b83a13d1fc848e48231f77a302e4a28
Autor:
Daniel S. Childs, David A. Helfinstine, Lindsey Sangaralingham, Jacob J. Orme, Ciara C. O'Sullivan, Charles L. Loprinzi, Kathryn J. Ruddy
Publikováno v:
JCO Oncology Practice. 18:e1953-e1960
PURPOSE: For the past 5 years, most major antiemesis guidelines have included olanzapine-containing regimens among the recommended options for prophylaxis with highly emetogenic chemotherapy (HEC). We analyzed the uptake of olanzapine in clinical pra
Autor:
Dhauna, Karam, Robert A, Vierkant, Shawna, Ehlers, Rachel A, Freedman, Jessica, Austin, Sadia, Khanani, Nicole L, Larson, Charles L, Loprinzi, Fergus, Couch, Janet E, Olson, Kathryn J, Ruddy
Publikováno v:
Journal of Geriatric Oncology. 13:1038-1042
Although the benefits of surveillance mammography for older breast cancer survivors have not been quantified prospectively, it is unlikely that mammography provides substantial benefit (and possible that mammography is harmful) to women with limited